GlassScriptPhysician profile
Rose L Gonzalez
NPI 1013255397
$6,605.43
in general payments reported to CMS, 2019-2025
27 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,948 · 2022: $2,572 · 2023: $1,806 · 2024: $161 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,986 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,985.65 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,077.91 | 2021-2023 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Abbvie INC. | $925.37 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $715.83 | 2021-2023 | |
| Alkermes, INC. | $644.56 | 2021-2023 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $600.99 | 2021-2023 | Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $523.34 | 2021-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $320.24 | 2021-2023 | Trintellix |
| Corium, LLC | $294.26 | 2021-2023 | Azstarys, Adlarity |
| Teva Pharmaceuticals USA, INC. | $277.52 | 2021-2023 | Austedo, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $217.08 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $200.54 | 2021-2025 | |
| Eisai INC. | $152.93 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $151.01 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $97.61 | 2021-2023 | |
| Axsome Therapeutics, INC. | $71.37 | 2023 | Auvelity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $48.78 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $37.01 | 2022 | |
| Biogen, INC. | $35.44 | 2021-2022 | |
| Abiomed | $35.24 | 2024 | Impella |
| Merck Sharp & Dohme LLC | $29.52 | 2021 | |
| Idorsia Pharmaceuticals US INC | $28.22 | 2023 | Quviviq |
| Arbor Pharmaceuticals, INC. | $27.62 | 2021 | |
| Ambu INC. | $22.85 | 2024 | |
| Nevro Corp. | $22.56 | 2023 | Senza |
| Indivior INC. | $16.24 | 2022 | |
| Jazz Pharmaceuticals INC. | $16.12 | 2021 | |
| Tris Pharma INC | $15.27 | 2023 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.